130 related articles for article (PubMed ID: 33475938)
1. AD80, a multikinase inhibitor, exhibits antineoplastic effects in acute leukemia cellular models targeting the PI3K/STMN1 axis.
Carlos JAEG; Lima K; Costa-Lotufo LV; Leitão A; Machado-Neto JA
Invest New Drugs; 2021 Aug; 39(4):1139-1149. PubMed ID: 33475938
[TBL] [Abstract][Full Text] [Related]
2. GDP366, a novel small molecule dual inhibitor of survivin and Op18, induces cell growth inhibition, cellular senescence and mitotic catastrophe in human cancer cells.
Shi X; Wang D; Ding K; Lu Z; Jin Y; Zhang J; Pan J
Cancer Biol Ther; 2010 Apr; 9(8):640-50. PubMed ID: 20160501
[TBL] [Abstract][Full Text] [Related]
3. AD80, a multikinase inhibitor, as a potential drug candidate for colorectal cancer therapy.
de Almeida LC; Carlos JAEG; Rezende-Teixeira P; Machado-Neto JA; Costa-Lotufo LV
Life Sci; 2022 Nov; 308():120911. PubMed ID: 36030982
[TBL] [Abstract][Full Text] [Related]
4. Targeting PDK1 with dichloroacetophenone to inhibit acute myeloid leukemia (AML) cell growth.
Qin L; Tian Y; Yu Z; Shi D; Wang J; Zhang C; Peng R; Chen X; Liu C; Chen Y; Huang W; Deng W
Oncotarget; 2016 Jan; 7(2):1395-407. PubMed ID: 26593251
[TBL] [Abstract][Full Text] [Related]
5. Synthetic cyclopenta[b]indoles exhibit antineoplastic activity by targeting microtubule dynamics in acute myeloid leukemia cells.
Vicari HP; Lima K; Gomes RDC; Fernandes DC; da Silva JCL; Rodrigues Junior MT; Barroso de Oliveira AS; Dos Santos RN; Andricopulo AD; Coelho F; Costa-Lotufo LV; Machado-Neto JA
Eur J Pharmacol; 2021 Mar; 894():173853. PubMed ID: 33422507
[TBL] [Abstract][Full Text] [Related]
6. IGF1R/IRS1 targeting has cytotoxic activity and inhibits PI3K/AKT/mTOR and MAPK signaling in acute lymphoblastic leukemia cells.
Rodrigues Alves APN; Fernandes JC; Fenerich BA; Coelho-Silva JL; Scheucher PS; Simões BP; Rego EM; Ridley AJ; Machado-Neto JA; Traina F
Cancer Lett; 2019 Aug; 456():59-68. PubMed ID: 31042587
[TBL] [Abstract][Full Text] [Related]
7. Targeting Wnt/β-catenin and PI3K/Akt/mTOR pathways in T-cell acute lymphoblastic leukemia.
Evangelisti C; Chiarini F; Cappellini A; Paganelli F; Fini M; Santi S; Martelli AM; Neri LM; Evangelisti C
J Cell Physiol; 2020 Jun; 235(6):5413-5428. PubMed ID: 31904116
[TBL] [Abstract][Full Text] [Related]
8. Antitumor action of CDK inhibitor LS-007 as a single agent and in combination with ABT-199 against human acute leukemia cells.
Xie S; Jiang H; Zhai XW; Wei F; Wang SD; Ding J; Chen Y
Acta Pharmacol Sin; 2016 Nov; 37(11):1481-1489. PubMed ID: 27569395
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of PI3K/mTOR Pathways with GDC-0980 in Pediatric Leukemia: Impact on Abnormal FLT-3 Activity and Cooperation with Intracellular Signaling Targets.
Al-Ghabkari A; Perinpanayagam MA; Narendran A
Curr Cancer Drug Targets; 2019; 19(10):828-837. PubMed ID: 30914027
[TBL] [Abstract][Full Text] [Related]
10. The Multikinase Inhibitor AD80 Induces Mitotic Catastrophe and Autophagy in Pancreatic Cancer Cells.
Lima K; de Miranda LBL; Del Milagro Bernabe Garnique A; de Almeida BO; do Nascimento MC; Alcântara GAS; Machado-Santelli GM; Rego EM; Machado-Neto JA
Cancers (Basel); 2023 Jul; 15(15):. PubMed ID: 37568682
[TBL] [Abstract][Full Text] [Related]
11. Cabozantinib is selectively cytotoxic in acute myeloid leukemia cells with FLT3-internal tandem duplication (FLT3-ITD).
Lu JW; Wang AN; Liao HA; Chen CY; Hou HA; Hu CY; Tien HF; Ou DL; Lin LI
Cancer Lett; 2016 Jul; 376(2):218-25. PubMed ID: 27060207
[TBL] [Abstract][Full Text] [Related]
12. PI3K Abrogation Using Pan-PI3K Inhibitor BKM120 Gives Rise to a Significant Anticancer Effect on AML-Derived KG-1 Cells by Inducing Apoptosis and G2/M Arrest.
Sadeghi S; Esmaeili S; Pourbagheri-Sigaroodi A; Safaroghli-Azar A; Bashash D
Turk J Haematol; 2020 Aug; 37(3):167-176. PubMed ID: 32160736
[TBL] [Abstract][Full Text] [Related]
13. Metformin synergistically sensitizes FLT3-ITD-positive acute myeloid leukemia to sorafenib by promoting mTOR-mediated apoptosis and autophagy.
Wang F; Liu Z; Zeng J; Zhu H; Li J; Cheng X; Jiang T; Zhang L; Zhang C; Chen T; Liu T; Jia Y
Leuk Res; 2015 Dec; 39(12):1421-7. PubMed ID: 26505133
[TBL] [Abstract][Full Text] [Related]
14. The novel arylindolylmaleimide PDA-66 displays pronounced antiproliferative effects in acute lymphoblastic leukemia cells.
Kretzschmar C; Roolf C; Langhammer TS; Sekora A; Pews-Davtyan A; Beller M; Frech MJ; Eisenlöffel C; Rolfs A; Junghanss C
BMC Cancer; 2014 Feb; 14():71. PubMed ID: 24502201
[TBL] [Abstract][Full Text] [Related]
15. Antiproliferative potential of a novel parthenin analog P16 as evident by apoptosis accompanied by down-regulation of PI3K/AKT and ERK pathways in human acute lymphoblastic leukemia MOLT-4 cells.
Goswami A; Shah BA; Kumar A; Rizvi MA; Kumar S; Bhushan S; Malik FA; Batra N; Joshi A; Singh J
Chem Biol Interact; 2014 Oct; 222():60-7. PubMed ID: 25196075
[TBL] [Abstract][Full Text] [Related]
16. Comprehensive analysis of cytoskeleton regulatory genes identifies ezrin as a prognostic marker and molecular target in acute myeloid leukemia.
Lipreri da Silva JC; Coelho-Silva JL; Lima K; Vicari HP; Lazarini M; Costa-Lotufo LV; Traina F; Machado-Neto JA
Cell Oncol (Dordr); 2021 Oct; 44(5):1105-1117. PubMed ID: 34196912
[TBL] [Abstract][Full Text] [Related]
17. A combination of temsirolimus, an allosteric mTOR inhibitor, with clofarabine as a new therapeutic option for patients with acute myeloid leukemia.
Chiarini F; Lonetti A; Teti G; Orsini E; Bressanin D; Cappellini A; Ricci F; Tazzari PL; Ognibene A; Falconi M; Pagliaro P; Iacobucci I; Martinelli G; Amadori S; McCubrey JA; Martelli AM
Oncotarget; 2012 Dec; 3(12):1615-28. PubMed ID: 23271044
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of mTOR kinase as a therapeutic target for acute myeloid leukemia.
Tabe Y; Tafuri A; Sekihara K; Yang H; Konopleva M
Expert Opin Ther Targets; 2017 Jul; 21(7):705-714. PubMed ID: 28537457
[TBL] [Abstract][Full Text] [Related]
19. The CDK9 Inhibitor Dinaciclib Exerts Potent Apoptotic and Antitumor Effects in Preclinical Models of MLL-Rearranged Acute Myeloid Leukemia.
Baker A; Gregory GP; Verbrugge I; Kats L; Hilton JJ; Vidacs E; Lee EM; Lock RB; Zuber J; Shortt J; Johnstone RW
Cancer Res; 2016 Mar; 76(5):1158-69. PubMed ID: 26627013
[TBL] [Abstract][Full Text] [Related]
20. New insights into Notch1 regulation of the PI3K-AKT-mTOR1 signaling axis: targeted therapy of γ-secretase inhibitor resistant T-cell acute lymphoblastic leukemia.
Hales EC; Taub JW; Matherly LH
Cell Signal; 2014 Jan; 26(1):149-61. PubMed ID: 24140475
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
